You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
福森藥業(01652.HK)指必要時增產雙黃連口服液 股價飆升53%曾見20元紀錄高
阿思達克 02-03 11:39

近幾個月為中港流感高峰期,且近期「武肺」疫情持續擴散,於2018年7月才以每股2.08元在港上市的領先品牌雙黃連類感冒藥製造商--福森藥業(01652.HK)指必要時調整「雙黃連口服液」產能 該股今早突破去年9月所創上市高位8元,最多飆升近2.5倍至20元上市新高遇阻,現造8.8元,急漲53%,一向薄弱成交激增至1,441萬股,僅次於首掛日成交量,涉資1.44億元。

福森就近期有媒體報導,集團主要產品之一「雙黃連口服液」具有可抑制新型冠狀病毒功效指出,目前集團尚未對此開展任何研究活動,亦未就有關功效作出任何聲明及保證。不過,公司將密切監察新型冠狀病毒及「雙黃連口服液」市場需求的發展,並在必要時審視及調整「雙黃連口服液」的產能,以滿足市場需求。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account